[HTML][HTML] Dolutegravir or darunavir in combination with zidovudine or tenofovir to treat HIV
…, G Ategeka, J Hakim, H Mugerwa… - … England Journal of …, 2021 - Mass Medical Soc
Background The World Health Organization recommends dolutegravir with two nucleoside
reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
reverse-transcriptase inhibitors (NRTIs) for second-line treatment of human …
[HTML][HTML] Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda
S Kansiime, D Mwesigire, H Mugerwa - PloS one, 2019 - journals.plos.org
Introduction Antiretroviral therapy (ART) has changed the course of HIV/AIDs by enabling
patients to live longer, raising concern of the co- existence of HIV with other chronic illnesses, …
patients to live longer, raising concern of the co- existence of HIV with other chronic illnesses, …
[HTML][HTML] Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection …
…, A Lugemwa, G Ategeka, M Borok, H Mugerwa… - The Lancet …, 2022 - thelancet.com
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line …
transcriptase inhibitors (NRTIs) for second-line HIV therapy, with NRTI switching from first-line …
[HTML][HTML] Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in …
S Nabukeera, J Kagaayi, FE Makumbi, H Mugerwa… - PLoS …, 2021 - journals.plos.org
Background While the proportion of HIV-positive children (under 15 years) enrolled on
antiretroviral therapy (ART) has increased in recent years, up to 60% of children started on ART …
antiretroviral therapy (ART) has increased in recent years, up to 60% of children started on ART …
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial
…, VM Balanag, RJ Castillo, H Mugerwa… - The Lancet Infectious …, 2023 - thelancet.com
Background Shorter treatments are needed for drug-susceptible tuberculosis. Adjunctive
statins increase bactericidal activity in preclinical tuberculosis models. We investigated the …
statins increase bactericidal activity in preclinical tuberculosis models. We investigated the …
Urine lipoarabinomannan testing in adults with advanced human immunodeficiency virus in a trial of empiric tuberculosis therapy
…, D Lagat, C Wallis, H Mugerwa… - Clinical Infectious …, 2021 - academic.oup.com
Background The urine lipoarabinomannan (LAM) antigen test is a tuberculosis (TB) diagnostic
test with highest sensitivity in individuals with advanced human immunodeficiency virus (…
test with highest sensitivity in individuals with advanced human immunodeficiency virus (…
[HTML][HTML] Towards access for all: 1st working group report for the global gene therapy initiative (GGTI)
…, P Malik, V Mathews, A McKemey, H Mugerwa… - Gene Therapy, 2023 - nature.com
The gene and cell therapy field saw its first approved treatments in Europe in 2012 and the
United States in 2017 and is projected to be at least a $10B USD industry by 2025. Despite …
United States in 2017 and is projected to be at least a $10B USD industry by 2025. Despite …
Efficacy of Cipargamin (KAE609) in a Randomized, Phase II Dose-Escalation Study in Adults in Sub-Saharan Africa With Uncomplicated Plasmodium falciparum …
…, MP Grobusch, E Karita, H Mugerwa… - Clinical Infectious …, 2022 - academic.oup.com
Background Cipargamin (KAE609) is a potent antimalarial in a phase II trial. Here we report
efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin …
efficacy, pharmacokinetics, and resistance marker analysis across a range of cipargamin …
Pharmacokinetics and safety of twice-daily ritonavir-boosted atazanavir with rifampicin
K Gausi, H Mugerwa, M Siccardi… - Clinical Infectious …, 2023 - academic.oup.com
Background Critical drug-drug interactions (DDI) and hepatotoxicity complicate concurrent
use of rifampicin and protease inhibitors. We investigated whether dose escalation of …
use of rifampicin and protease inhibitors. We investigated whether dose escalation of …
[HTML][HTML] Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose …
…, KP Asante, MP Grobusch, E Karita, H Mugerwa… - Malaria journal, 2021 - Springer
Background The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against
Plasmodium falciparum. Transient asymptomatic liver function test elevations were …
Plasmodium falciparum. Transient asymptomatic liver function test elevations were …